Solutions
The Complete Evidence Platform
Patented biomarker panel with forensic-grade chain-of-custody. From order to report — standardized and audit-ready.
4
Biomarkers
6
Step Process
99.6%
NPV (CT prediction)
$5,500
Flat Fee
The Challenge
What Imaging Misses
Without Biomarkers
- ✕Normal CT/MRI used against patient
- ✕Symptoms labeled "subjective"
- ✕Defense argues malingering
- ✕No measurable injury timeline
- ✕Claims routinely minimized
With NWP Biomarkers
- ✓Molecular injury detected in blood
- ✓Objective, lab-verified evidence
- ✓Severity graded by biomarker levels
- ✓Recovery tracked over time
- ✓Audit-ready forensic documentation
Core Panel
Four Markers
GFAP
Acute Detection
Detects glial injury. FDA-cleared.
Window: 0–24 hrs
Sensitivity: 92%
NfL
Progression
Tracks axonal damage over time.
Window: Days–Months
Sensitivity: 78%
APOE
Prognostic
Genetic risk for worse outcomes.
Window: Lifetime
p-Tau217
Future Risk
Links injury to neurodegeneration.
Window: Weeks–Years
Evidence System
Three Layers of Value
Measurement
FDA-cleared blood biomarkers detecting injury at the molecular level.
Process
Patented end-to-end workflow from order through final report.
Evidentiary Integrity
Full chain-of-custody and audit-ready documentation.
Workflow
Six Steps. Fully Standardized.
1
Order
2
Collect
3
Document
4
QA/QC
5
Analyze
6
Report
Applications
Where It Applies
Investment
Simple Pricing
$5,500
Recoverable case cost
4-marker panel
Chain-of-custody
Audit-ready report
Request a Briefing
Learn how the biomarker evidence platform can support your cases, programs, or clinical operations.
